SAN FRANCISCO The U.S. Court of Appeals for the Ninth Circuit affirmed a pharmaceutical executive’s groundbreaking conviction Monday for misstating clinical study results in a company press release.
Turning back W. Scott Harkonen’s claim that the conviction criminalizes genuine scientific debate, the court upheld his wire fraud conviction for misrepresenting the therapeutic value of Actimmune. "Harkonen’s scientific methods were not on trial; the issue was whether he misleadingly presented his analyses in the press release," the Ninth Circuit stated in an unpublished, per curiam opinion.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
